MRC Technology Announces Humanization of Anti-Tau Monoclonal Antibody for Alzheimers Disease Therapy
![](/46/pdcnewsitem/03/34/67/Hl5FTIU8KV4mO3c.jpg)
MRC Technology has successfully humanized an anti-tau monoclonal antibody, which has applications in the treatment of Alzheimer’s and related neurodegenerative tauopathies. The humanized tau antibody represents an important milestone for developing a disease modifying immunotherapy for Alzheimer’s disease. MRC Technology was contracted to humanize the antibody by AXON Neuroscience SE, a biotechnology company dedicated to the development of disease modifying immunotherapeutics and early diagnostics for Alzheimer's disease.
Alzheimer’s disease is characterized by the presence of neurofibrillary tangles consisting of diseased forms of protein tau. Tau cortical neurofibrillary tangles correlate well with the severity of cognitive impairment in Alzheimer’s disease and thus represent a valuable target for disease modifying therapy. Targeting disease modified tau appears to be a promising way to slow down or even stop progression of the disease.
Michael Dalrymple, Director of Business Development at MRC Technology, said: "We are very pleased with the outcome of this project and are hopeful that the positive evaluation results for the humanized antibody will prove to be a milestone in the development of effective treatments for this debilitating disease.”
“Treatment of Alzheimer’s disease is still recognised as an unmet medical need. Our company has considerable expertise in the area and I believe we are on the right track to developing an effective therapy that has the potential to stop progress of the disease,” commented Roman Sivak, Chief Executive Officer at AXON Neuroscience. “We thank MRC Technology for their invaluable support in humanizing this antibody, an essential step in its development as an immune-based therapeutic.”
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance